

POST OFFER ADVERTISEMENT UNDER REGULATION 18(12) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AS AMENDED ("SEBI (SAST) REGULATIONS")
FOR THE ATTENTION OF PUBLIC SHAREHOLDERS OF

HINDUSTAN AGRIGENETICS LIMITED

Corporate Identification Number (CIN): L01119DL1990PLC040979
Registered Office: C-1/5, Second Floor, Safdurjung Development Area, New Delhi – 110016
(shifted from 806, Meghdoot, 94 Nehru Place, New Delhi 110019
pursuant to a resolution passed at the Board Meeting of the Target Company held on January 17, 2025)
Tel. No.: +91-9810273609; Fax No.: NA
Email: hindustanagrigenetics@gmail.com; Website: www.hindustanagrigenetics.co.in

Open Offer for Acquisition of up to **11,44,052 (Eleven Lakh Forty Four Thousand and Fifty Two Only)** Equity Shares representing 26% of the fully diluted voting share capital from the Equity Shareholders of Hindustan Agrigenetics Limited ("Target Company") by **Mr. Rajendra Naniwadekar ("Acquirer")** at a price of **₹ 54/-** per fully paid-up equity share.

This Post Offer Advertisement is being issued by Bajaj Capital Securities Limited (Formerly known as Bajaj Capital Holdings Limited) ("Manager to the Offer"), on behalf of Acquirer in connection with the offer made by the Acquirer, in compliance with Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended ("SEBI (SAST) Regulations, 2011"). The Public Announcement ("PA"), Detailed Public Statement ("DPS"), Corrigendum to DPS cum Pre-Offer Advertisement and the Corrigendum to Pre-Offer Advertisement with respect to the aforementioned offer was published on January 13, 2025, January 20, 2025, September 01, 2025 and September 06, 2025 respectively in Financial Express (English – all edition), Jansatta (Hindi – all edition), and Navshakti (Marathi).

1	Name of the Target Company	Hindustan Agrigenetics Limited			
2	Name of the Acquirer and PACs	Mr. Rajendra Naniwadekar ("Acquirer"), No Person is acting in concert with the Acquirer.			
3	Name of the Manager to the Offer	Bajaj Capital Securities Limited			
4	Name of the Registrar to the Offer	KFin Technologies Limited			
5	Offer Details:				
	a) Date of Opening of the Offer	September 09, 2025 (Tuesday)			
	b) Date of Closure of the Offer	September 22, 2025 (Monday)			
6	Date of Payment of Consideration	September 29, 2025 (Monday)			
7	Details of Acquisition				
Sl. No	Particulars	Proposed in the Offer Document (Letter of Offer)		Actuals	
7.1	Offer Price	₹ 54/- per Fully paid up equity share.		₹ 54/- per Fully paid up equity share.	
7.2	Aggregate number of shares tendered	11,44,052		1,432	
7.3	Aggregate number of shares accepted	11,44,052		1,432	
7.4	Size of the Offer (Number of shares multiplied by offer price per share)	6,17,78,808		77,328	
7.5	Shareholding of the Acquirer and PACs before Agreements / Public Announcement (No. & %)	10,60,496 (24.10%)		10,60,496 (24.10%)	
7.6	Shares Acquired by way of Share Purchase Agreement (SPA) • Number • % of Fully Diluted Equity Share Capital	44,000 (1.00%)		44,000 (1.00%)	
7.7	Shares Acquired by way of Open Offer • Number • % of Fully Diluted Equity Share Capital	11,44,052 (26.00%)		1,432 (0.03%)	
7.8	Shares acquired after Detailed Public Statement* • Number of shares acquired • Price of the shares acquired • % of the shares acquired	3,300 50 0.07%		3,300 50 0.07%	
7.9	Post offer shareholding of Acquirer along with PACs • Number • % of Fully Diluted Equity Share Capital	22,48,548 (51.10%)		11,05,928 (25.13%)	
7.10	Pre & Post offer shareholding of the Public** • Number • % of Fully Diluted Equity Share Capital	Pre Offer 29,97,588 68.12%	Post Offer 18,53,536 42.12%	Pre Offer*** 30,08,659 68.38%	Post Offer*** 30,23,305 68.71%

- *3,300 equity shares held by Chandni Kapur, member of the Promoter group of the Target Company which were agreed to be acquired and paid for by the Acquirer prior to the date of the PA, were transferred to the Acquirer on March 13, 2025, after the date of DPS.
- **The Open offer is issued to all the shareholders of the Target Company excluding the Promoter and Promoter Group and the Acquirer.
- ***Pre-Offer data is based on the benpos dated September, 5, 2025. Post offer data is based on benpos dated September, 19, 2025.
8. The Acquirer accepts full responsibility for the information contained in this Post Offer Advertisement and also for the obligations under SEBI (SAST) Regulations, 2011.
9. The Acquirer has consummated the Share Purchase Agreement transaction in accordance with the provisions of Regulations 22(1), 22(3) of the SEBI (SAST) Regulations and clause 7 of the Share Purchase Agreement (SPA) and has already given an intimation to the Target Company for reclassification of himself as the promoter of the Target Company, in accordance with the provisions of Regulation 31A(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, including subsequent amendments thereto (SEBI (LODR) Regulations')
10. **A copy of this Post Offer Advertisement will be made available on the websites of SEBI, BSE Limited and of the Target Company.
11. The capitalized terms used but not defined in this advertisement shall have the meanings assigned to such terms in the PA and/or DPS and/or LOF.
12. This Post offer Advertisement is being issued in all the newspapers in which the DPS has appeared.

ISSUED BY THE MANAGER TO THE OFFER ON BEHALF OF THE ACQUIRER



Bajaj Capital Securities Limited
(formerly Bajaj Capital Holdings Limited)
Mezzanine Floor 97, Bajaj House, Nehru Place, New Delhi -110019, India
Tel No: +91 11 - 67000000
Contact Person: G.Akila
Email: info@bajajcapitalsec.com
Website: www.bajajcapitalsec.com
SEBI Registration Number: INM000013208

Place: Hyderabad
Date: October 03, 2025

THE BUSINESS DAILY.

FINANCIAL EXPRESS

FOR DAILY BUSINESS.

financialexpress.com

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever. Registered letters are not accepted in response to box number advertisement."

For Advertising in TENDER PAGES

Contact JITENDRA PATIL

Mobile No.: 9029012015

Landline No.: 67440215

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



(Scan this code to view Draft Red Herring Prospectus)

PUBLIC ANNOUNCEMENT



Goldline Pharmaceutical Limited

GOLDLINE PHARMACEUTICAL LIMITED

Goldline Pharmaceutical Limited (the "Issuer" or our "Company") was incorporated on August 02, 2004 as "Goldline Pharmaceutical Private Limited", a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 02, 2004 issued by the Registrar of Companies, Maharashtra at Mumbai. Further, our Company was converted into a public limited company pursuant to a resolution passed by the Shareholders in an extraordinary general meeting held on July 18, 2013 and consequently the name of our Company was changed to "Goldline Pharmaceutical Limited" and a fresh certificate of incorporation dated September 23, 2013 was issued by the Registrar of Companies, Maharashtra at Mumbai. The corporate identity number of our Company is U51397MH2004PLC147806. For details of change in Registered Office of our Company, please refer to the chapter titled "History and Certain Corporate Matters" on page 171 of the Draft Red Herring Prospectus.
Corporate Identity Number: U51397MH2004PLC147806
Registered Office: 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur – 440 015, Maharashtra, India;
Corporate Office: N.A.; Telephone: +91 712 278 6666; Contact Person: Ruchi Sanket Modi, Company Secretary & Compliance Officer;
Website: www.goldlinepharma.in; E-mail: info@goldlinepharma.in

DETAILS OF THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 30,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF OUR COMPANY AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ [•] LACS ("PUBLIC ISSUE") OUT OF WHICH [•] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [•] LACS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [•] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [•] LACS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [•] % AND [•] % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.
THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [•] EDITIONS OF [•] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), [•] EDITIONS OF [•] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND MARATHI EDITIONS OF [•]), A REGIONAL LANGUAGE NEWSPAPER (MARATHI, BEING THE REGIONAL LANGUAGE OF MAHARASHTRA, WHERE OUR REGISTERED OFFICE IS SITUATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE") FOR THE PURPOSES OF UPLOADING ON ITS WEBSITE IN ACCORDANCE WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").
This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229(2) of the SEBI ICDR Regulations and in compliance with Regulation 253(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors, wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than ₹10 lakhs; and (c) any unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non-Institutional Investors and not less than 35% of the Net Issue shall be available for allocation to Individual Investors who apply for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 284 of the Draft Red Herring Prospectus.
This public announcement is made in compliance with Regulation 247 of the SEBI ICDR Regulation along with Notification no.: F.No. SEBI/LADNRO/GN/2025/233 dated March 3, 2025 and Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2025, to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Issue and had filed the DRHP dated September 30, 2025 which has been filed with SME Platform of BSE Limited ("BSE").
In relation to above, the DRHP filed SME Platform of BSE Limited ("BSE") shall be made available to the public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the respective websites of the Stock Exchange i.e., BSE Limited at www.bseindia.com, website of the Company at www.goldlinepharma.in and the website of the Book Running Lead Manager to the Issue i.e., Cumulative Capital Private Limited at www.cumulativecapitalgroup ("BRLM"). Our Company hereby invites the members of the public to give comments on the DRHP filed with SME Platform of BSE Limited with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of their comments to SME Platform of BSE Limited and/or to the Company Secretary & Compliance Officer of our Company and/or the BRLM and/or Registrar to the Issue at their respective addresses mentioned herein below in relation to the Issue on or before 5:00 p.m. on the 21st day from the aforesaid date of filing the DRHP with SME Platform of BSE Limited.
Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 22 of the Draft Red Herring Prospectus. Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered, through the RHP, are proposed to be listed on the SME Platform of BSE Limited.
For details of the main objects of our Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on page 171 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see "Capital Structure" beginning on page 70 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY
 CUMULATIVE CAPITAL PRIVATE LIMITED Address: 321, 3rd Floor, C Wing, 215 Atrium Co. Op Premises, Andheri Kurla Road, Hanuman Nagar-400093, Andheri Mumbai Telephone: +91 8200052280 / +91-9936798144 E-mail: contact@cumulativecapitalgroup Website: www.cumulativecapitalgroup Investor Grievance E-mail: contact@cumulativecapitalgroup Contact Person: Jigar Bhanushali / Parin Dhanesha SEBI Registration Number: INM000013129	 Bigshare Services Private Limited Address: S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai – 400 093, Maharashtra, India. Telephone: +91 22 6263 8200 Facsimile: +91 22 6263 8299 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Contact Person: Ganesh Shinde SEBI Registration Number: INF000001385	 GOLDLINE PHARMACEUTICAL LIMITED 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur – 440 015, Maharashtra, India Telephone: +91 712 278 6666 E-mail: info@goldlinepharma.in Website: www.goldlinepharma.in Contact Person: Ruchi Sanket Modi, Company Secretary and Compliance Officer CIN: U51397MH2004PLC147806

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP dated September 30, 2025.

GOLDLINE PHARMACEUTICAL LIMITED
on behalf of the Board of Directors
Sd/-
Ruchi Sanket Modi
Company Secretary & Compliance Officer

Goldline Pharmaceutical Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated September 30, 2025 with Stock Exchange. The DRHP shall be available on the website of the Stock Exchange i.e. BSE Limited at www.bseindia.com, website of the Company at www.goldlinepharma.in and the website of the Book Running Lead Manager to the Issue i.e., Cumulative Capital Private Limited at www.cumulativecapitalgroup. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 22 of the Draft Red Herring Prospectus. Potential investors should not rely on the DRHP filed with the Stock Exchanges for making any investment decision, and should instead rely on the RHP for making investment decision.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or any state securities law in United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This announcement has been prepared for publication in India and may not be released in the United States.
This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended, or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. There will be no public offering of the Equity Shares in the United States.



ASSETS CARE & RECONSTRUCTION ENTERPRISE LTD.
CIN : U65993DL2002PLC115769
Regd. Office : 14th Floor, Eros Corporate Tower, Nehru Place, New Delhi - 110019. Tel : 91-11-43115600 | Fax : 91-11-43115618
Corporate Office : Unit No. : 502, C Wing, One BKC, Radius Developers, Plot No. : C-66, G-Block, Bandra Kurla Complex, Mumbai – 400051. Tel. : 022 68643101 | E-mail : acre.acre@acreindia.in | Website : www.acreindia.in

APPENDIX IV-A SALE NOTICE FOR SALE OF IMMOVABLE PROPERTIES

E-auction Sale Notice for sale of Immovable Assets under the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 read with proviso to Rule 8(6) & 9(1) of The Security Interest (Enforcement) Rules, 2002.
Notice is hereby given to public in general and in particular to the Borrower(s), Co-Borrower(s), Mortgagee(s) and Guarantor(s) that the below described Immovable Properties mortgaged/charged to **Assets Care & Reconstruction Enterprise Ltd.** [CIN: U65993DL2002PLC115769] ("**Secured Creditor**"), the physical possession of which has been taken by the Authorised Officer of the Secured Creditor, will be sold on "**as is where is**", "**as is what is**" and "**whatever there is**" basis for the recovery of amount due to Secured Creditor from the following Borrower(s), Co-Borrower(s), Mortgagee(s) and Guarantor(s) along with the Reserve Price and Earnest Money Deposit mentioned below for each property:
DETAILS OF SECURED ASSET

Sr. No.	Loan Account No. & ACRE TRUST Name	Name of Borrower(s) Co-Borrower(s) Mortgagee(s)/Guarantors	Total Outstanding Dues as on 30 September 2025	Reserve Price	Earnest Money Deposit	Bank Account Details for EMD payment
1	7763700000740, 0018BM06201070002, 001PCFC190840007, 001PCFC190950009, 196LA17181590002, 0018BM06201060002, 196LA17181590001, 7784600001940 and 7784600002031 ACRE-166-TRUST	Global Import Exports Through its Proprietor Manik Chawla, Deepthi Chawla	Rs.9,82,87,093/- (Rupees Nine Core Eighty-Two Lakhs Eighty-Seven Thousand Ninety-Three Only) 7763700000740, 0018BM06201070002, 001PCFC190840007, 001PCFC190950009, 196LA17181590002, 0018BM06201060002, 196LA17181590001, 7784600001940 and 7784600002031	Rs. 2,80,00,000/- (Rupees Two Crores Eighty Lakhs Only)	Rs. 28,00,000/- (Rupees Twenty Eight Lakhs Only)	Account Name: ACRE-166-TRUST Account Number: 0901102000042112 Bank: IDBI Bank IFSC Code: IBKL0000901

DESCRIPTION OF THE SECURED ASSET: Flat No 604 6th Floor Liliium Co-operative Society Limited Sector No. R-12 Nahar Amrut Shakti Chandivli Andheri(e)/Mumbai Along With Two Car Parking Space -400072.
The above Loan Account(s) along with all right(s), title(s), interest(s), underlying security(ies), pledge(s) and/ or guarantee(s), including the Immovable Properties, mentioned hereinabove had been assigned to Assets Care & Reconstruction Enterprise Ltd., acting as a trustee of various trust mentioned clearly in column provided above.

IMPORTANT INFORMATION REGARDING AUCTION PROCESS

1	EMD payment through demand draft/RTGS/NEFT shall be drawn/paid in favor of the bank accounts mentioned above	
2	Date & time of Auction	27th October 2025, 2:30 PM to 3:30 PM
3	Last date of submission of EMD	24th October 2025 before 4:00 PM
5	Place of auction (Web Site for Auction) -	www.auctionfocus.in
6	Contact Details	Mr. Rohan Sawant - 9833143013 Mr. Hari Nair - 9846098098
7	Inspection of the Property on prior appointment basis only	
8	For detailed terms and condition of the sale, please visit the website www.acreindia.in / www.auctionfocus.in	

Date : 03.10.2025
Place : Mumbai

Sd/-
Authorized Officer
Assets Care & Reconstruction Enterprise Ltd.

epaper.financialexpress.com

महाविद्यालयाच्या नामकरण फलकाचे उद्घाटन

FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT
OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT
DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT

HIGHNESS™
One of a kind

HIGHNESS MICROELECTRONICS PRIVATE LIMITED
Formerly known as Highness Microelectronics Private Limited)
Corporate Identification Number: U72900MH2007PTC173854

As a Private limited company under the Companies Act, 1956 in the name and style of bearing Corporate Identification Number U72900MH2007PTC173854 dated September 6, Mumbai. Subsequently, our Company was converted into a Public Limited Company vide shares at the Extra Ordinary General Meeting, held on August 31, 2024 and consequently the "Highness Microelectronics Private Limited" to "Highness Microelectronics Limited" vide a November 11, 2024 issued by the Registrar of Companies, Mumbai bearing CIN registered office of the company situated at: Office 1C3, 1st Floor, Gundecha Onclave, Mumbai- 400072, Maharashtra. For further details, please refer to section titled "Our History" on page No. 161 of this Draft Red Herring Prospectus.

3, 1st Floor, Gundecha Onclave, Kherani Road, Saki Vihar, Andheri (East), Mumbai- 400072, Maharashtra

s. Preeti Paresh Rathi **Email Id:** investor@highnessmicro.com
91- 022-28507123; **Website:** www.highnessmicro.com

Gaurav Manjul Kejriwal, Mr. Manjul Kumar Kejriwal and Mrs. Shruti Gaurav Kejriwal

IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED.)"

THE OFFER

06,000,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF HIGHNESS MICROELECTRONICS OR THE "OFFEROR") FOR CASH AT A PRICE OF ₹ [●]- PER EQUITY SHARE OF ₹ [●]- PER EQUITY SHARE (THE "OFFER PRICE") AGGREGATING TO ₹ [●]- OF ₹ [●]- OF A PER ISSUE UPTO 16,53,600 EQUITY SHARES AGGREGATING TO ₹ [●]- OF ₹ [●]- OF AN OFFER FOR SALE OF UPTO 38,400 EQUITY SHARES BY PROMOTER SELLING KEJRIWAL AND MR. MANJUL KUMAR KEJRIWAL AGGREGATING TO ₹ [●]-

‘अॅड पार्क’ योजना

नवी मुंबई हे नियोजित शहर निवेशा अधिक वाहने झाल्याने परण केले आहे. त्यावर उतारा ठरवण्यासाठी ठिकाणी ‘पे अॅड पार्क’ योजना लागू करण्यात आली आहे. या योजनेअधीक वाहनांना पार्किंगसाठी ठिकाणी तसे वेशिस्त पार्किंगला जात आहे.

अधीक कमी-अधिक प्रमाणात वाहनात पार्किंगसाठी सोबीडी आणि ठिकाण समस्या आहे. वाशीत पार्किंग समस्यावर स्लॅब टाकून ठिकाणी आखलेल्या ‘पे अॅड पार्क’ योजनेअधीक २२ ठिकाणी पार्किंग ठिकाणासाठी निविदा मागवण्यात आली आणि २,७६८ चारचकी ठिकाणी समस्या द्यावा केला जात आहे. या योजनेअधीक जागेच्या कमतरतेमुळे ठिकाणी जागा मिळेल तिथे त्यांची ठिकाणी कोडी वाढते. ही समस्या ठिकाणी लालली आहे. अनेकदा वाहने ठिकाणी खेळत्या मैदानामध्येही

10% PER EQUITY SHARE INCLUSION AND SHALL BE RESERVED FOR RESERVATION PORTION”), THE OFFER SHARES OF FACE VALUE OF ₹ 10/- PER EQUITY SHARE AGGREGATE OFFER AND THE NET OFFER WILL BE SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUMUM AND WILL BE ADVERTISED IN [●] EDITION OF [●] (A WIDELY CIRCULATED REGIONAL NEWSPAPER (MARATHI LOCATED), AT LEAST TWO WORKING DAYS BEFORE THE COMMENCEMENT OF THE SME PLATFORM OF BSE LIMITED.

In case of any revision in the Price Band of the revision of the Price Band, subject to the or similar unforeseen circumstances, our one working day, subject to the Bid/Offer Period, if applicable, shall be widely disseminated the change on the website of the BRL Intermediaries and Sponsor Bank.

This Offer is being made under the BSE 1957, as amended (“SCRR”) read with the ICDR Regulations wherein not more than Institutional Buyers (“QIBs”) (the “QIB Portion to Anchor Investors on a basis of which one-third shall be reserved for above the Anchor Investor Allocation Portion balance Equity Shares shall be added to of the Net QIB Portion shall be available). Portion shall be available for allocation or received at or above the Offer Price. How balance Equity Shares available for allocation to QIBs. Further, not less than Institutional Investors (where one third application size of more than two lots and

Net Offer shall be available for allocation to individual investors who applies to SEBI (CDR) Regulations, subject to valid Bids being received from them at or above the Offer Price. Anchor Investors are required to mandatorily utilize the Application Supported by Blocked Bank (ASBA) Accounts, and UPIID in case of IBs using the UPI Mechanism as per SEBI (CDR) Regulations, 2025. Anchor Investors will not be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as Anchor Investors are not permitted to participate in the Offer through the ASBA Platform. For details, please refer to the Offer through the ASBA Platform on page 256 of this Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulations (Amendment) Regulations, 2025 vide notification dated March 03rd, 2025, and SEBI (LODR) Regulations, 2015 on SME companies to inform the public that the Company is offering its Equity Shares pursuant to the offer and DRHP dated September 30, 2024, Limited.

Pursuant to SEBI (CDR) (Amendment) Regulations, 2025 on March 03rd, 2025, under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all the requirements of the SME Platform of BSE Limited (BSE SME) shall be made available to the public for the purpose of date of such filing by hosting it on the website of the BSE at <https://www.bseindia.com> and on the website of BRLM of the Company at www.highgrowthmco.com and at the website of BRLM of the Company at www.intellectadvisors.com. Our Company hereby invites the members of the SME Platform of BSE Limited (BSE SME) with respect to disclosures made in this prospectus to visit the website of the BSE and BRLM to view the details of the copy of their comments to Stock Exchange, to Company Secretary and Company Compliance Officer mentioned below. All comments must be received by the Company Compliance Officer of our Company and/or the BRLM in relation to the offer on or before the filing of the DRHP with BSE SME.

Investments in Equity and Equity related securities involve a degree of risk and investors can only expect to realize a return on their investment. Investors are advised to consult their investment advisers in the Offer. For taking an investment decision, investors must consider the risks involved in the Offer. The Equity Shares issued in the Offer have not been listed on the Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or completeness of the information in the prospectus. The attention of the investors is invited to the section "Risk Factors" beginning on page 10 of this prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of the information contained in the Draft Red Herring Prospectus. The Company does not intend to change in the Red Herring Prospectus from the Draft Red Herring Prospectus. The prospectus, are proposed to be listed on SME Platform of BSE LIMITED ("BSE SME") and the public number of shares subscribed by them of our Company, see "Capital Structure" section of the prospectus. The liability of the members of our Company is limited. For details, please refer to the Memorandum of Association, see "Our History and Certain Other Corporate Information" section of the prospectus.

[illegible]

१९. ऑर्गना कॉम्प्लेक्स, मुंबई - ४०००४९. ia.in	Prospectus.
	BOOK RUNNING LEAD MANAGER

राकम ठेव	इसे प्रदानकारिता बँक खाते तथापील
रु. ०,०००/- अठ्ठावीस मात्र)	खाते नाव : एसीआरई - १९६६ - टुट्ट खाते क्र. : ०९०११००००००११११ बँक : आसदीलाल बँक आपकापील बँक आयबीकेल ००००१०१

नाहार अमन शक्ति बांदिल्ली अंधेरी (ई)

दुस केअर अँड रिक्निडरन एएएआयसे

[illegible]

Specifically defined shall have the same meaning as ascribed to them in the DRHP.

Fo

For Highness Microelectronics Limited

On Behalf of the Board of Directors

Sd/-

Ms. Preeti Paresh Rathi

Company Secretary and Compliance Officer

I am proposing, subject to applicable statutory and regulatory requirements, receipt of your considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus dated 07-08-2025. The Draft Red Herring Prospectus is available on the website of BSE SME at www/SMEIPODRHP.aspx and is available on the websites of the BRLM at www.bseindia.com and the website of the Company www.highnessmicro.com. Any potential investors should note that securities involve a degree of risk and investors should not invest any funds in this offer of securities without having carefully considered all the risks involved therein and their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision, investors must rely on their own examination of our Company and the Equity Shares issued in the Offer have not been recommended or approved by the Securities and Exchange Board of India (SEBI) guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific reference is made to "Risk Factors" beginning on page 27 of this Draft Red Herring Prospectus.

The Equity Shares will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and may not be offered or sold within the United States or to, or for the benefit of, persons resident in the United States, except pursuant to exemption from, or in a transaction not prohibited by, the registration requirements of the U.S. Securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in reliance on Regulation S under the U.S. Securities Act and the offering is restricted so that no such offers and sale occur. The Equity Shares have not been and will not be registered under the Securities Act of 1933, and therefore they cannot be offered, sold, or applied for registration in any other jurisdiction outside India and may not be offered or sold, and application of the Securities Act of 1933, and therefore they cannot be offered, sold, or applied for registration in any other jurisdiction, except in compliance with the applicable laws of such jurisdiction.